Microbiological, Epidemiological, and Clinical Characteristics and Outcomes of Patients with Cryptococcosis in Taiwan, 1997-2010

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Tseng, Hsiang Kuang ^a,b,h,j   Liu, Chang Pan ^b,h,j   Ho, Mao Wang ^c   Lu, Po Liang ^d   Lo, Hsiu Jung ^e,f   Lin, Yu Hui ^g   Cho, Wen Long ^a,h   Chen, Yee Chun ⁱ  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b MACKAY MEMORIAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f CHINA MEDICAL UNIVERSITY   (Taiwan)

^g TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^h MACKAY MEDICAL COLLEGE   (Taiwan)

ⁱ NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^j NURSING AND MANAGEMENT COLLEGE   (Taiwan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; FUNGUS ANTIGEN; VORICONAZOLE;

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CHILD; CONTROLLED STUDY; CRYPTOCOCCEMIA; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DISEASE COURSE; FEMALE; FUNGEMIA; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RISK; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENINGOENCEPHALITIS; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; NONHUMAN; PULMONARY CRYPTOCOCCOSIS; RETROSPECTIVE STUDY; SCHOOL CHILD; TAIWAN;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CHILD; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DNA FINGERPRINTING; FEMALE; GENOTYPE; HOSPITALIZATION; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PHYLOGENY; RISK FACTORS; TAIWAN; TREATMENT OUTCOME; YOUNG ADULT;

CRYPTOCOCCUS GATTII; FILOBASIDIELLA NEOFORMANS;

EID: 84876204391     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061921     Document Type: Article

References (42)

1. Harris J, Lockhart S, Chiller T, (2012) Cryptococcus gattii: where do we go from here? Med Mycol 50: 113-129 doi:10.3109/13693786.2011.607854.
2. Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E, et al. (2003) Molecular typing of IberoAmerican Cryptococcus neoformans isolates. Emerg Infect Dis 9: 189-195 doi:10.3201/eid0902.020246.
3. Nucci M, Perfect JR, (2008) When primary antifungal therapy fails. Clin Infect Dis 46: 1426-1433 doi:10.1086/587101.
4. Bicanic T, Meintjes G, Wood R, Hayes M, Rebe K, et al. (2007) Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 45: 76-80 doi:10.1086/518607.
5. Dromer F, Bernede-Bauduin C, Guillemot D, Lortholary O, French Cryptococcosis Study G, (2008) Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE 3: e2870 doi:10.1371/journal.pone.0002870.
6. Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, et al. (2012) Cryptococcus neoformans- Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. Antimicrob Agents Chemother 56: 3107-3113 doi:10.1128/AAC.06252-11.
7. Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, et al. (2012) Cryptococcus neoformans- Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 56: 5898-5906 doi:10.1128/AAC.01115-12.
8. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, et al. (2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 101: 17258-17263 doi:10.1073/pnas.0402981101.
9. Clinical and Laboratory Standards Institute (2008) Reference method for broth dilution antifungal susceptibility testing of yeasts; approved standard. Wayne, PA: CLSI.
10. Pappas PG, Perfect JR, Cloud GA, Larsen RA, Pankey GA, et al. (2001) Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 33: 690-699 doi:10.1086/322597.
11. Chau TT, Mai NH, Phu NH, Nghia HD, Chuong LV, et al. (2010) A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam- high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease. BMC Infect Dis 10: 199 doi:10.1186/1471-2334-10-199.
12. Jain N, Wickes BL, Keller SM, Fu J, Casadevall A, et al. (2005) Molecular epidemiology of clinical Cryptococcus neoformans strains from India. J Clin Microbiol 43: 5733-5742 doi:10.1128/JCM.43.11.5733-5742.2005.
13. Tay ST, Rohani MY, Hoo TS, Hamimah H, (2010) Epidemiology of cryptococcosis in Malaysia. Mycoses 53: 509-514 doi:10.1111/j.1439-0507.2009.01750.x.
14. Feng X, Yao Z, Ren D, Liao W, Wu J, (2008) Genotype and mating type analysis of Cryptococcus neoformans and Cryptococcus gattii isolates from China that mainly originated from non-HIV-infected patients. FEMS Yeast Res 8: 930-938 doi:10.1111/j.1567-1364.2008.00422.x.
15. Choi YH, Ngamskulrungroj P, Varma A, Sionov E, Hwang SM, et al. (2010) Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HIV-associated cryptococcosis in the Republic of Korea. FEMS Yeast Res 10: 769-778 doi:10.1111/j.1567-1364.2010.00648.x.
16. Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, et al. (2008) Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis 14: 755-762 doi:10.3201/eid1405.071312.
17. Yuchong C, Fubin C, Jianghan C, Fenglian W, Nan X, et al. (2012) Cryptococcosis in China (1985-2010): review of cases from Chinese database. Mycopathologia 173: 329-335 doi:10.1007/s11046-011-9471-1.
18. Chen S, Sorrell T, Nimmo G, Speed B, Currie B, et al. (2000) Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Australasian Cryptococcal Study Group. Clin Infect Dis 31: 499-508 doi:10.1086/313992.
19. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O, French Cryptococcosis Study G, (2007) Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 4: e21 doi:10.1371/journal.pmed.0040021.
20. Olivares LR, Martinez KM, Cruz RM, Rivera MA, Meyer W, et al. (2009) Genotyping of Mexican Cryptococcus neoformans and C. gattii isolates by PCR-fingerprinting. Med Mycol 47: 713-721 doi:10.3109/13693780802559031.
21. Jean SS, Fang CT, Shau WY, Chen YC, Chang SC, et al. (2002) Cryptococcaemia: clinical features and prognostic factors. QJM 95: 511-518.
22. Antinori S, Galimberti L, Magni C, Casella A, Vago L, et al. (2001) Cryptococcus neoformans infection in a cohort of Italian AIDS patients: natural history, early prognostic parameters, and autopsy findings. Eur J Clin Microbiol Infect Dis 20: 711-717.
23. Shih CC, Chen YC, Chang SC, Luh KT, Hsieh WC, (2000) Cryptococcal meningitis in non-HIV-infected patients. QJM 93: 245-251.
24. Chen YC, Chang SC, Shih CC, Hung CC, Luhbd KT, et al. (2000) Clinical features and in vitro susceptibilities of two varieties of Cryptococcus neoformans in Taiwan. Diagn Microbiol Infect Dis 36: 175-183 doi:S0732-8893(99)00137-6 [pii].
25. Liaw SJ, Wu HC, Hsueh PR, (2010) Microbiological characteristics of clinical isolates of Cryptococcus neoformans in Taiwan: serotypes, mating types, molecular types, virulence factors, and antifungal susceptibility. Clin Microbiol Infect 16: 696-703 doi:10.1111/j.1469-0691.2009.02930.x.
26. Chang WN, Huang CR, Lei CB, Lee PY, Chien CC, et al. (2004) Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole. Jpn J Infect Dis 57: 113-115.
27. Lee CK (2011) [Isolation of Cryptococcus species and Tricosporon asahii from environment in southern Taiwan] [master thesis]. Kaohsiung City, Taiwan (R.O.C.): National Sun Yat-Sen University. 52 p.
28. Chaturvedi V, Chaturvedi S, (2011) Cryptococcus gattii: a resurgent fungal pathogen. Trends Microbiol 19: 564-571 doi:10.1016/j.tim.2011.07.010.
29. Varma A, Kwon-Chung KJ, (2010) Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob Agents Chemother 54: 2303-2311 doi:10.1128/AAC.00153-10.
30. Sionov E, Lee H, Chang YC, Kwon-Chung KJ, (2010) Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog 6: e1000848 doi:10.1371/journal.ppat.1000848.
31. Lee H, Khanal Lamichhane A, Garraffo HM, Kwon-Chung KJ, Chang YC, (2012) Involvement of PDK1, PKC and TOR signalling pathways in basal fluconazole tolerance in Cryptococcus neoformans. Mol Microbiol 84: 130-146 doi:10.1111/j.1365-2958.2012.08016.x.
32. Desnos-Ollivier M, Patel S, Spaulding AR, Charlier C, Garcia-Hermoso D, et al. (2010) Mixed infections and In Vivo evolution in the human fungal pathogen Cryptococcus neoformans. MBio 1. doi:10.1128/mBio.00091-10.
33. Sorrell TC, Chen SC, Ruma P, Meyer W, Pfeiffer TJ, et al. (1996) Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting. J Clin Microbiol 34: 1253-1260.
34. Campbell LT, Currie BJ, Krockenberger M, Malik R, Meyer W, et al. (2005) Clonality and recombination in genetically differentiated subgroups of Cryptococcus gattii. Eukaryot Cell 4: 1403-1409 doi:10.1128/EC.4.8.1403-1409.2005.
35. Escandon P, Sanchez A, Martinez M, Meyer W, Castaneda E, (2006) Molecular epidemiology of clinical and environmental isolates of the Cryptococcus neoformans species complex reveals a high genetic diversity and the presence of the molecular type VGII mating type a in Colombia. FEMS Yeast Res 6: 625-635 doi:10.1111/j.1567-1364.2006.00055.x.
36. Lui G, Lee N, Ip M, Choi KW, Tso YK, et al. (2006) Cryptococcosis in apparently immunocompetent patients. QJM 99: 143-151 doi:10.1093/qjmed/hcl014.
37. MacDougall L, Kidd SE, Galanis E, Mak S, Leslie MJ, et al. (2007) Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg Infect Dis 13: 42-50 doi:10.3201/eid1301.060827.
38. Byrnes EJ 3rd, Bildfell RJ, Frank SA, Mitchell TG, Marr KA, et al. (2009) Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J Infect Dis 199: 1081-1086 doi:10.1086/597306.
39. Byrnes EJ 3rd, Li W, Lewit Y, Perfect JR, Carter DA, et al. (2009) First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS ONE 4: e5851 doi:10.1371/journal.pone.0005851.
40. Okamoto K, Hatakeyama S, Itoyama S, Nukui Y, Yoshino Y, et al. (2010) Cryptococcus gattii genotype VGIIa infection in man, Japan, 2007. Emerg Infect Dis 16: 1155-1157 doi:10.3201/eid1607.100106.
41. Cogliati M, Chandrashekar N, Esposto MC, Chandramuki A, Petrini B, et al. (2012) Cryptococcus gattii serotype-C strains isolated in Bangalore, Karnataka, India. Mycoses 55: 262-268 doi:10.1111/j.1439-0507.2011.02082.x.
42. Sellers B, Hall P, Cine-Gowdie S, Hays AL, Patel K, et al. (2012) Cryptococcus gattii: an emerging fungal pathogen in the southeastern United States. Am J Med Sci 343: 510-511 doi:10.1097/MAJ.0b013e3182464bc7.